WO1985003000A1 - Formulations de dosage liquide a liberation regulee pour produits pharmaceutiques - Google Patents

Formulations de dosage liquide a liberation regulee pour produits pharmaceutiques Download PDF

Info

Publication number
WO1985003000A1
WO1985003000A1 PCT/US1985/000042 US8500042W WO8503000A1 WO 1985003000 A1 WO1985003000 A1 WO 1985003000A1 US 8500042 W US8500042 W US 8500042W WO 8503000 A1 WO8503000 A1 WO 8503000A1
Authority
WO
WIPO (PCT)
Prior art keywords
coating
dosage forms
liquid
controlled release
dual coated
Prior art date
Application number
PCT/US1985/000042
Other languages
English (en)
Inventor
Ben Franklin Benton
David Lee Gardner
Original Assignee
Battelle Development Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Development Corporation filed Critical Battelle Development Corporation
Priority to JP60500315A priority Critical patent/JPS61500910A/ja
Publication of WO1985003000A1 publication Critical patent/WO1985003000A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Definitions

  • This invention relates to controlled release pharmaceuticals, specifically dual-coated controlled re ⁇ lease pharmaceuticals as a liquid dosage formulation which have substantial shelf life. More particularly, this invention relates to and discloses liquid suspens- ions of dual coated controlled release dosage forms that retain their controlled release characteristics even though dispersed in a liquid medium for a significant period of time prior to use.
  • Controlled release forms of medication are well known in the art. Some such medications are prepared as tablets in the form of a therapeutically active core coated with various thicknesses of ingestible materials. Other time release medications take the form of an in- nocuous core coated with alternating layers of thera ⁇ Terminally active materials and inactive ingestible ma ⁇ terials. More recently microcapsules or microspheres, with selected proportions of the microcapsules having coatings of differing solubilities, have been placed in conventional gelatin capsules to yield controlled release dosage forms.
  • Dosage form is defined as referring to the solid carrier or housing vehicle for a therapeutically active compound exhibiting controlled release.
  • a dosage form would include any type of common prill, and would also include, for example, tab ⁇ lets, capsules, matrix materials, microcapsules, reser- voir type tablets, and microspheres.
  • Controlled release is understood to mean re ⁇ lease, preferably uniform release, of the active compound over a span of time, thus would encompass such terms as time-release, delayed release, and sustained release.
  • Dosage formulation is defined as referring to the combination of dosage forms and liquid carrier in which the dosage forms are dispersed.
  • the present invention relates to and discloses compositions for making liquid suspensions of controlled release dosage forms of therapeutically active compounds that retain their controlled release characteristics even though dispersed in a liquid medium for a significant period of time prior to use.
  • the present invention can be applied to and suc ⁇ cessfully used with any known solid controlled release pharmaceutical to convert it into a liquid dosage formu ⁇ lation having significant shelf life while still re ⁇ taining an acceptable controlled release profile upon ingestion.
  • the present invention can be applied to and used with tablets, capsules, matrix materials, micro- capsules, reservoir-type tablets, microspheres and any other type of controlled release dosage form capable of being coated.
  • the present invention discloses use of a unique combination dual coating of fats overcoated with cel- lulose derivatives or prolamins and a liquid carrier for achieving a versatile liquid controlled release dosage formulation having substantial shelf life prior to in ⁇ proof.
  • the present invention is a controlled release liquid dosage formulation for pharmaceuticals.
  • the pres ⁇ ent invention discloses use of a unique combination of dual coatings of controlled release type dosage forms in combination with a suitable liquid carrier.
  • Suitable con ⁇ trolled release type dosage forms useful in the practice of the present invention include tablets, capsules, con- trolled-release matrix beads, microcapsules, reservoir- type tablets, and microspheres, all by way of example and not limitation.
  • suitable controlled release type dosage forms are coated with at least two different materials.
  • the first coating is with a hydrophobic, digestible or degradable material preferably having a melting point of approximately 120°F or lower such that the coating would be almost liquid or rendered permeable following ingestion.
  • the first coat ⁇ ing over said dosage forms can be a lipid including a fat, a fatty acid, fatty alcohol, wax, ester or mixtures thereof, having a melting point of less than 120°F.
  • the first coating preferably is one or more fats, i.e., glycerides composed of fatty acids of from 3 to 22 carbons, with said glycerides or blends of glycerides having a melting point of 120°F or less.
  • the fats or glycerides include minor percentages of sterols, hydrocarbons, to- copherols and other nonglyceride constituents.
  • the fats or glycerides can include mono-, di-, or triglycerides or glyceryl esters, phosphatides, phosphoglycerides, or mix ⁇ tures thereof.
  • the first coating is, preferably, a hard butter such as cocoa butter, or partially hydrogenated cottonseed and/or soybean vegetable oil such as Kaomel* (Durkee) which has a Wileymelting point of 97-101°F.
  • Also useful for the first coatings are: animal fats, tallow; shortening; lard including modified lard; vegetable oils including partially hydrogenated vegetable oils; beeswax; lecithin; butterfat; oleic acid; elaidic acid; margarine; or blends of any of the foregoing.
  • melting point is an approximate term when applied to fats, waxes, fatty acids and esters since these materials melt over a range of temperature.
  • the first coating can be a fat, fatty acid, fatty alcohol, wax, ester, or mixture thereof having a melting point of less than approximately 120°F or capable of being rendered permeable following ingestion.
  • Substances useful as the first coating include mono-, di-, and triglycerides composed of fatty acids of from 3 to 32 carbons; wax esters composed of fatty acids of from 3 to 36 carbons and composed of alcohols of from 8 to 46 carbons; fatty alcohols of from 8 to 54 carbons; hydrocarbons of from 18 to 54 carbons; olefins of from 18 to 54 carbons, and free fatty acids of 8 to 36 carbons, all additionally having a melting point below approximately 120°F or capable of being rendered permeable following ingestion.
  • the waxes making up the first coating can in ⁇ clude, by way of illustration and not limitation; wax hydrocarbons - such as n - alkanes and branched alkanes, olefins, cyclic alkanes and isoprenoid hydrocarbons; ketones such as monoketones, 8- diketones, wax alcohols - such as secondary alcohols and alkane diols, wax acids - such as alkanoic and alkenoic acids, - or ⁇ - hydroxy acids, and wax esters - such as primary alcohol esters, secondary alcohol esters, diester waxes, alkane diol di- esters, diesters of hydroxy acids, triesters, trigly- cerides, triesters of alkane -1,2 -diol, ⁇ - hydroxy acid and fatty acid; esters of hydroxy malonic acid,,fatty acid and alcohol; triesters of hydroxy acids, fatty acid and fatty alcohol; triesters
  • an overcoat or second coating is provided which is: 1) amenable to being render ⁇ ed permeable in early portions of the gastrointestinal tract, preferably within approximately the first hour of entering the gastrointestinal tract; and 2) able to pre ⁇ vent agglomeration or clumping of the coated microcap ⁇ sules or microspheres.
  • Compounds useful for the second coating or overcoating include: the prolamins, such as zein, glia- din, or hordein; also carotin; also starch and its deriva ⁇ tives; also cellulose derivatives, such as the dibasic acid monoester derivatives of cellulose including cellu ⁇ lose acetate phthalate and cellulose acetate succinate, also cellulose derivatives such as carboxymethyl cellu- lose acetate, carboxymethyl ethyl cellulose, carboxy ⁇ methyl hydroxypropyl cellulose acetate, carboxymethyl cellulose stearic acid, also cellulose ethers such as ethyl cellulose. Compatible blends of any of the fore ⁇ going can also be used.
  • the prolamins such as zein, glia- din, or hordein
  • carotin also starch and its deriva ⁇ tives
  • cellulose derivatives such as the dibasic acid monoester derivatives of cellulose including cellu ⁇ lose a
  • the second coating should be selected so as to be generally nonsoluble in the carrier liquid, however, rendered permeable in the gastrointestinal tract.
  • Vari ⁇ ous means of rendering the second coating permeable can be employed.
  • the second coating can be pH sensitive, meaning soluble in only a limited range of pH i.e., alkaline soluble in the GI tract; or the second coating can be broken down by enzymes such as Upases, proteases, or a alases, i.e., the second coating, can be a protein which is broken down by any of various proteases in the gastrointestinal tract; or the second coating can be a starch broken down by enzymes such as amalase within the GI tract.
  • the preferred materials for the second coating or overcoating are zein or cellulose acetate phthalate.
  • plasticizer such as diethyl ptha- late, tributyl citrate, tributyrin; triacetin, castor oil, partially or fully acetylated monoglycerides or butyl phthalyl butyl glycolate can be employed in either or both coatings to impart desired or what is deemed suitable flexibility, workability or resiliency to the coating.
  • the plasticizer can also be used to modify the permeability of the respective coating.
  • the dual coated microspheres or dual coated controlled release dosage form can be dispersed in the carrier or delivery liquid medium.
  • water may be used as the carrier liquid it is preferred to add thickeners to assure uniform dispersion.
  • liquid carriers which diminish the amount of available water such as aqueous solutions of colloidal carbohy ⁇ drates or sugar syrups.
  • suitable carrier liquids can be employed, such as, by way of illustration and not limitation, high fructose corn syrup, honey, sugar syrup, an aqueous solution of carboxymethyl cellulose, glycerin, gum arabic, agar, or gelatin. Miscible combinations of the foregoing are also possible.
  • the delivery medium is chosen so as to reduce the proportion of water available to leach the active drug from the dual coated dosage form, but also to-be palat ⁇ able to the recipient of the liquid dosage formulation.
  • Slightly acid carrier liquids are preferred since they also tend to retard microbial growth.
  • High fructose corn syrup was found to be a particularly suitable delivery medium as such syrup has only approximately 30% water and is naturally acidic.
  • the liquid carrier is best selected so as to be a poor solvent of the particular pharmaceutic.
  • Sugar solutions and sugar syrups are useful as the carrier liquid from the aspect of limiting the avail- able water but also as a preservative.
  • any of the foregoing liquids can be used as the carrier liquid inwhich the dual coated dosage forms are dispersed, it is advantageous where possible to select a carrier liquid such that the active drug held in the dual coated dosage form is not soluble or only minimally solu- ble in the carrier liquid.
  • the present in ⁇ vention provides an improved delivery vehicle for con ⁇ trolled release dosage forms, which dosage forms are understood to include controlled-release matrix beads, microspheres, microcapsules, or reservoir type capsules or devices, by enabling preparing of liquid formulations of such dosage forms having a substantial shelf life.
  • dosage forms are understood to include controlled-release matrix beads, microspheres, microcapsules, or reservoir type capsules or devices, by enabling preparing of liquid formulations of such dosage forms having a substantial shelf life.
  • Microspheres, microcapsules, and matrix beads are pre ⁇ ferred dosage forms, especially in the size range of 15 microns to 7000 microns.
  • microspheres and controlled release dosage forms useful for the purposes of being dual coated accord ⁇ ing to the invention can be prepared by any of several known microencapsulation processes or microsphere or ma- trix bead production processes including pan coating, prilling, granulation fluidization processes, pressing through fine mesh screens and other processes.
  • controlled release microspheres packageable and administrable in a liquid formulation intended for young children or the elderly can also be practiced with any of the earlier-mentioned controlled release type dosage forms.
  • controlled- release tablets, capsules, devices, spheres or matrix beads coated according to the present invention can pro ⁇ vide dosage forms suitable for preparation in a liquid formulation, for example, in veterinary applications, where micro sizes become relative to the size of the recipient.
  • the liquid suspension of dual coated controlled release dosage forms according to this invention can be prepared in advance in many cases as early as 35 days or sooner before the intended day of administration of the liquid formulation.
  • the controlled release characteristics of the dual coated microspheres are expressed with active drug release commencing in the upper gastrointestinal tract and active drug release continuing at a uniform rate thereafter for at least 8-12 or 24 hours.
  • the controlled release liquid dosage formu ⁇ lations of the present invention are particularly suit ⁇ able for such drugs as theophylline, dimethylxanthine, antihistamines, cold formulations, analgesics, amino acid supplements, geriatric drugs such as sleeping aids and blood pressure regulators, antidepressants such as lith ⁇ ium chloride, also potassium salts, and alkaloids such as caffeine and codeine.
  • Theophylline was selected to illustrate the dual coated dosage form and liquid dosage formulation of the present invention.
  • Theophylline was selected to illustrate the scope of the invention since a suitable liquid dosage formulation, especially one in which the ⁇ ophylline is the therapeutically active compound, must satisfy a particularly rigid controlled-release profile.
  • Theophylline is a representative alkaloid drug. lt is isomeric with dimethylxanthine and the common alka ⁇ loid, caffeine, differs from theophylline by one less methyl group.
  • Theophylline, typical of alkaloids, is bitter.
  • Theophylline is used as an antiasthmatic but it has an unpleasant taste and requires careful dose mea ⁇ surement and administration to maintain therapeutic serum concentrations. Especially with young children, the now required every 4-6 hour round-the-clock dosing levels of theophylline are difficult to administer and maintain. c hildren often dislike the taste.
  • theophyl ⁇ line is a tissue irritant and thus is preferred to be administered in an enteric release form.
  • the preferred controlled release liquid dosage formulation containing theophylline according to this invention should satisfy the rigid criteria of:
  • liquid dosage formu- lation of the present invention is particularly advan- tageous for the administering of theophylline.
  • a liquid dosage formulation sustaining theophylline release up to 12 or 24 hours according to this invention would_.be parti ⁇ cularly beneficial to asthmatic children, would be easy to administer because of the liquid carrier and its masking of the unpleasant taste, and would require less frequent administration.
  • the premixed liquid dosage formulation would be practical for dispensing by pharmacies.
  • Examples of five commercially available con ⁇ trolled release type dosage forms are illustrated below.
  • the active drug is theophylline in these preparations.
  • Aerolate*, 1, 2 and 4 grain capsules (Flem- ming and Company, St. Louis, Missouri) .
  • Sustaire* tablet (Roerig, Division of Pfi ⁇ zer, Inc., New York, New York). Based upon the release profile of these sus ⁇ tained release type products, the Theo-Dur* scored tab ⁇ lets and Slo-Phylline Gyrocaps* when placed into apple ⁇ sauce exemplify the typical "liquid dosage formulation" available today. Tested for release of theophylline via serum levels it was found that after 1 hour, the Theo-dur ⁇ scored tablets had released 10% of their theophylline and the Slo-Phylline Gyrocaps* had released 80% of their theo ⁇ phylline.
  • the typical controlled release dosage form available today does not have any significant shelf life in an aqueous based carrier fluid since appreciable re- lease proceeds from the initial time of dispersion in the carrier liquid.
  • Typical sustained release dosage forms in the 5 form of spherical beads or microspheres are readily ob ⁇ tained from commercial sources.
  • the micro ⁇ spheres were obtained from Central Pharmaceuticals, Inc. ,
  • a plas ⁇ ticizer was included to enhance the coating properties of the zein and CAP.
  • the plasticizer used was 05 Myvacet* (Eastman Kodak) a distilled acetylated mono- glyceride.
  • cellulose acetate pthalate a butyl ptha- lyl-butyl glycolate liquid sold as Sanitizer* (Pfizer) was used as a plasticizer.
  • coated dosage forms were 10 prepared for testing (all percents given are by weight) .
  • the (D) in vitro release study was similar to the (B) and (C) _in vitro release studies with the exception of duration, temperature and test solution. All (D) jln vitro release studies were conducted at 37 C by placing the test tubes on the Lab Quake rotator in a thermostatistic- ally-controlled oven. The test solution for this in vitro release study was a simulated gastric fluid during the first hour followed by a simulated intestinal fluid.
  • the simulated gastric fluid was prepared as follows:
  • the simulated intestinal fluid was prepared as follows: 6.8 g of monobasic potassium phosphate was dis ⁇ solved in 250 ml of water. With stirring, 190 ml of 0.2 N sodium hydroxide was added along with 400 ml of water. 10 g of pancreatin was then added with stirring. The pH of the resulting solution was adjusted to apH of 7.5 + 0.1 by the addition of 0.2 N sodium hydroxide, then the so ⁇ lution was diluted with water to 1000 ml.
  • Theophylline release in the simulated gastric fluid test solution followed by simulated intestinal fluid test solution was determined at the end of 1, 2, 3, 4, 5, 6 and 8 hours.
  • Table 3 ⁇ show that when the dosage form is placed in high fructose corn syrup, HFCS, an acidic environment, several dosage forms show extremely low levels of theophylline release.
  • type #4 dosage form released only 0.2 percent of the available theophylline over a 14-day period.
  • the uncoated dosage form under these same condi ⁇ tions and duration released 14.8% of the available the ⁇ ophylline.
  • Another four types #'s 5, 7, 8 and 10 exhibited less than 1 percent release after 7 days.
  • the reduced amount of theophylline released is due primarily to the coatings placed over the controlled release dosage forms.
  • the low percentage of water in the HFCS i.e., 29 percent, tends to further minimize the amount of theophylline which 5 is released.
  • Theophylline solubility in water 8.3 mg/ml.
  • the results of the (B) and (C) in vitro release studies verify the importance of the liquid carrier pH in which the dosage form will be eventually formulated. For instance, in Table 4, the lowest per- Q centage of theophylline release from the #4 type dosage form was 47.1%. However, in Table 5, when this same type #4 dosage form was placed in an acidic environment (pH 4.5) , the theophylline release had dropped to 1.8%. Addi ⁇ tionally, the dosage form overcoated with Kaomel®-CAP produced the least amount of theophylline release. The importance of these two coatings, i.e., Kaomel* and CAP, is clearly established if compared with dosage form types #8 and #9 (See Table 5) . Table 3 Results of In Vitro Release Study (A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

Produits pharmaceutiques à libération entretenue de forme de dosage liquide à revêtement double, possédant une durée limite de stockage substantiel avant l'ingestion. Le revêtement double est appliqué sur des formes de dosage à libération régulée et comporte généralement des lipides comme des graisses ou des cires fondant à une température inférieure à environ 120oF, enduits de prolamine ou de dérivés de la cellulose. Les formes de dosage à revêtement double sont dispersées dans un porteur liquide comme un sirop de maïs à forte teneur en fructose et présentent une durée limite de stockage pouvant aller jusqu'à environ au moins 35 jours tout en conservant leurs profils à libération régulée après l'ingestion.
PCT/US1985/000042 1984-01-13 1985-01-09 Formulations de dosage liquide a liberation regulee pour produits pharmaceutiques WO1985003000A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60500315A JPS61500910A (ja) 1984-01-13 1985-01-09 薬剤用制御放出性液状製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57046984A 1984-01-13 1984-01-13
US570,469 1984-01-13

Publications (1)

Publication Number Publication Date
WO1985003000A1 true WO1985003000A1 (fr) 1985-07-18

Family

ID=24279767

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1985/000042 WO1985003000A1 (fr) 1984-01-13 1985-01-09 Formulations de dosage liquide a liberation regulee pour produits pharmaceutiques

Country Status (11)

Country Link
EP (1) EP0169236A1 (fr)
JP (1) JPS61500910A (fr)
AU (1) AU3835885A (fr)
CA (1) CA1239347A (fr)
ES (1) ES8605975A1 (fr)
GR (1) GR850069B (fr)
IL (1) IL74049A0 (fr)
IT (1) IT1184309B (fr)
NZ (1) NZ210785A (fr)
WO (1) WO1985003000A1 (fr)
ZA (1) ZA85239B (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302065A1 (fr) * 1986-03-21 1989-02-08 Eurasiam Lab Compositions pharmaceutiques.
GR880100297A (en) * 1987-05-08 1989-02-23 Orion Yhtymae Oy A new synthesis / composition
EP0313992A1 (fr) * 1987-10-26 1989-05-03 Alza Corporation Pluralité de petites pillules dans des formes de dosage liquides
EP0359195A2 (fr) * 1988-09-16 1990-03-21 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Système thérapeutique à libération contrôlée pour formulations pharmaceutiques liquides
US5030454A (en) * 1987-10-26 1991-07-09 Alza Corporation Method for delivering drug in tiny pills in liquid carrier
US5085868A (en) * 1986-12-22 1992-02-04 Astra Lakemedel Aktiebolag Liquid dosage form for all oral administration of a pharmaceutically active substance
EP0580428A1 (fr) † 1992-07-24 1994-01-26 Takeda Chemical Industries, Ltd. Préparation à base de microparticules et production de celle-ci
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
EP0619733A1 (fr) * 1991-12-31 1994-10-19 Abbott Laboratories Systeme d'apport d'une substance active a liberation prolongee
EP0620730A1 (fr) * 1991-12-31 1994-10-26 Abbott Laboratories Enrobages de prolamine pour masquer le gout de medicaments s'administrant par voie orale
EP0535937B1 (fr) * 1991-10-01 1997-06-11 Takeda Chemical Industries, Ltd. Préparation à base de microparticules à libération prolongée et production de celle-ci
US5700484A (en) * 1994-12-16 1997-12-23 Nestec S.A. Sustained release microparticulate caffeine formulation
WO2000059468A1 (fr) * 1999-04-06 2000-10-12 Laboratoires Des Produits Ethiques Ethypharm Suspension pharmaceutique buvable
FR2821745A1 (fr) * 2001-03-09 2002-09-13 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
US6794411B1 (en) 1999-04-06 2004-09-21 Laboratoire Des Produits Ethiques Ethypharm Drinkable ibuprofen pharmaceutical suspension
WO2004096175A2 (fr) * 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Compositions au gout masque et leurs procedes de preparation
US10682338B2 (en) 2014-09-05 2020-06-16 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
GB931149A (en) * 1958-12-22 1963-07-10 Upjohn Co Dual coating process
DE1467976A1 (de) * 1963-09-18 1969-01-16 Key Pharma Traegermassen fuer Pharmazeutika und Verfahren zu ihrer Herstellung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
GB931149A (en) * 1958-12-22 1963-07-10 Upjohn Co Dual coating process
DE1467976A1 (de) * 1963-09-18 1969-01-16 Key Pharma Traegermassen fuer Pharmazeutika und Verfahren zu ihrer Herstellung

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302065A4 (en) * 1986-03-21 1990-09-12 Eurasiam Laboratories, Inc. Pharmaceutical compositions
EP0302065A1 (fr) * 1986-03-21 1989-02-08 Eurasiam Lab Compositions pharmaceutiques.
US5085868A (en) * 1986-12-22 1992-02-04 Astra Lakemedel Aktiebolag Liquid dosage form for all oral administration of a pharmaceutically active substance
FR2630912A1 (fr) * 1987-05-08 1989-11-10 Orion Yhtymae Oy Composition permettant d'administrer un medicament sous forme de gelules, d'une poudre ou d'un liquide
BE1000785A3 (fr) * 1987-05-08 1989-04-04 Orion Yhtymae Oy Composition permettant d'administrer un medicament sous forme de gelules, d'une poudre ou d'un liquide.
GR880100297A (en) * 1987-05-08 1989-02-23 Orion Yhtymae Oy A new synthesis / composition
EP0313992A1 (fr) * 1987-10-26 1989-05-03 Alza Corporation Pluralité de petites pillules dans des formes de dosage liquides
US5030454A (en) * 1987-10-26 1991-07-09 Alza Corporation Method for delivering drug in tiny pills in liquid carrier
EP0359195A2 (fr) * 1988-09-16 1990-03-21 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Système thérapeutique à libération contrôlée pour formulations pharmaceutiques liquides
EP0359195A3 (fr) * 1988-09-16 1991-04-24 RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY Système thérapeutique à libération contrôlée pour formulations pharmaceutiques liquides
US5405619A (en) * 1988-09-16 1995-04-11 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for liquid pharmaceutical formulations
US5296236A (en) * 1988-09-16 1994-03-22 Recordati S.A., Chemical And Pharmaceutical Company Controlled release therapeutic system for a liquid pharmaceutical formulations
US5510119A (en) * 1988-09-16 1996-04-23 Recordati S.A., Chemical And Pharmaceuticl Company Controlled release therapeutic system for liquid pharmaceutical formulations
EP0535937B1 (fr) * 1991-10-01 1997-06-11 Takeda Chemical Industries, Ltd. Préparation à base de microparticules à libération prolongée et production de celle-ci
EP0620730A4 (fr) * 1991-12-31 1995-05-17 Abbott Lab Enrobages de prolamine pour masquer le gout de medicaments s'administrant par voie orale.
EP0619733A4 (fr) * 1991-12-31 1995-06-07 Abbott Lab Systeme d'apport d'une substance active a liberation prolongee.
EP0619733A1 (fr) * 1991-12-31 1994-10-19 Abbott Laboratories Systeme d'apport d'une substance active a liberation prolongee
EP0620730A1 (fr) * 1991-12-31 1994-10-26 Abbott Laboratories Enrobages de prolamine pour masquer le gout de medicaments s'administrant par voie orale
EP0580428B2 (fr) † 1992-07-24 2002-05-29 Takeda Chemical Industries, Ltd. Préparation à base de microparticules et production de celle-ci
EP0580428A1 (fr) † 1992-07-24 1994-01-26 Takeda Chemical Industries, Ltd. Préparation à base de microparticules et production de celle-ci
US5700484A (en) * 1994-12-16 1997-12-23 Nestec S.A. Sustained release microparticulate caffeine formulation
US5744164A (en) * 1994-12-16 1998-04-28 Nestec S.A. Sustained release microparticulate caffeine formulation
US6794411B1 (en) 1999-04-06 2004-09-21 Laboratoire Des Produits Ethiques Ethypharm Drinkable ibuprofen pharmaceutical suspension
FR2791888A1 (fr) * 1999-04-06 2000-10-13 Ethypharm Lab Prod Ethiques Suspension pharmaceutique buvable
WO2000059468A1 (fr) * 1999-04-06 2000-10-12 Laboratoires Des Produits Ethiques Ethypharm Suspension pharmaceutique buvable
FR2821745A1 (fr) * 2001-03-09 2002-09-13 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
WO2002072072A3 (fr) * 2001-03-09 2002-12-27 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
WO2004096175A2 (fr) * 2003-04-30 2004-11-11 Ranbaxy Laboratories Limited Compositions au gout masque et leurs procedes de preparation
WO2004096175A3 (fr) * 2003-04-30 2005-01-13 Ranbaxy Lab Ltd Compositions au gout masque et leurs procedes de preparation
US10682338B2 (en) 2014-09-05 2020-06-16 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis
US10849884B2 (en) 2014-09-05 2020-12-01 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis
US10857133B2 (en) 2014-09-05 2020-12-08 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis
US11000507B2 (en) 2014-09-05 2021-05-11 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis
US11000508B2 (en) 2014-09-05 2021-05-11 Lupin Inc. Secnidazole for use in the treatment of trichomoniasis
US11020377B2 (en) 2014-09-05 2021-06-01 Lupin Inc. Secnidazole for use in the treatment of bacterial vaginosis
US11324721B2 (en) 2014-09-05 2022-05-10 Lupin Inc. Secnidazole for use in the treatment of trichomoniasis
US11602522B2 (en) 2014-09-05 2023-03-14 Lupin Inc. Secnidazole for use in the treatment of sexually transmitted infection
US11684607B2 (en) 2014-09-05 2023-06-27 Lupin, Inc. Secnidazole for use in the treatment of bacterial vaginosis

Also Published As

Publication number Publication date
CA1239347A (fr) 1988-07-19
ES539500A0 (es) 1986-04-01
ES8605975A1 (es) 1986-04-01
GR850069B (fr) 1985-05-03
JPS61500910A (ja) 1986-05-08
NZ210785A (en) 1987-11-27
IT1184309B (it) 1987-10-28
ZA85239B (en) 1985-08-28
IL74049A0 (en) 1985-04-30
IT8519086A0 (it) 1985-01-11
AU3835885A (en) 1985-07-30
EP0169236A1 (fr) 1986-01-29

Similar Documents

Publication Publication Date Title
US4876094A (en) Controlled release liquid dosage formulation
WO1985003000A1 (fr) Formulations de dosage liquide a liberation regulee pour produits pharmaceutiques
EP0619733B1 (fr) Systeme d'apport d'une substance active a liberation prolongee
US2410417A (en) Vitamin and mineral dietary supplement and method of making
US4415547A (en) Sustained-release pharmaceutical tablet and process for preparation thereof
KR910004573B1 (ko) 작용 지속형 세파클로르 제제의 제조 방법
DK175812B1 (da) Flydende præparat med forbedrede egenskaber til peroral administrering
AU2018100110A4 (en) Ubiquinone And Ubiquinol Compositions, And Methods Relating Thereto
RU1814559C (ru) Способ получени композиции инсулина дл орального введени
US4325942A (en) Ubidecarenone compositions having enhanced absorption properties
EP0106443A2 (fr) Formulation pharmaceutique orale à unités multiples, à libération contrôlée
KR910004595B1 (ko) 작용 지속형 피나시딜 제제의 제조방법
FI96095C (fi) Menetelmä jatkuvavapautteisen lääkevalmisteen valmistamiseksi
SK152397A3 (en) Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
EP0851758A1 (fr) Composition pharmaceutique
JP2008536879A (ja) 薬物又は栄養物の組合物調剤及び調合剤、その内服による吸収を改善する方法、及びその応用方法
CS396391A3 (en) Theophyline-containing retarded preparation
JP2005527207A (ja) 生理的に認容される、リン脂質を含有する、安定でかつ硬質のマトリックス
GB2134785A (en) Slow-release compositions
KR102419759B1 (ko) 고 약물 부하량의 중쇄 트리글리세라이드를 갖는 약학 조성물 및 이와 관련된 방법
US4397835A (en) Enterosoluble hard-capsulated medicaments
JPH02240016A (ja) 水分散性ジエムフイブロジル組成物
JPS5846013A (ja) グリコシド水解酵素抑制剤の新規薬剤調製物
JPH0952847A (ja) 徐放性製剤
CN100577178C (zh) 含有罗红霉素的软胶囊

Legal Events

Date Code Title Description
AK Designated states

Designated state(s): AU DK JP KR

AL Designated countries for regional patents

Designated state(s): AT BE CH DE FR GB LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985900864

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985900864

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1985900864

Country of ref document: EP